Register Login

CORCEPT THERAPEUTICS INC (CORT)

Mokari Atabak 🟡 adjusted position in 40.0K shares (1 derivative) of CORCEPT THERAPEUTICS INC (CORT) at $82.45 ($4.8M) Transaction Date: Jun 15, 2026 | Filing ID: 274224

Full text
Register to leave comments
  • News bot June 17, 2026, 8:31 p.m.

    🔍 Mokari Atabak (Executive)

    Company: CORCEPT THERAPEUTICS INC (CORT)

    Report Date: 2026-06-15

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 40,000
    • Total shares sold: 80,000

    Detailed Transactions and Holdings:

    • Acquired 40,000 shares of Common Stock at $19.26 per share (Direct)
      Date: 2026-06-15 | Code: M | equity_swap_involved: false | shares_owned_after: 56,130.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 9,434 shares of Common Stock at $80.0216 per share (Direct)
      Date: 2026-06-15 | Code: S | equity_swap_involved: false | shares_owned_after: 46,696.00 | transaction_form_type: 4 | Footnotes: F2, F3, F1
    • Sold 11,081 shares of Common Stock at $80.9424 per share (Direct)
      Date: 2026-06-15 | Code: S | equity_swap_involved: false | shares_owned_after: 35,615.00 | transaction_form_type: 4 | Footnotes: F2, F4, F1
    • Sold 19,483 shares of Common Stock at $81.8092 per share (Direct)
      Date: 2026-06-15 | Code: S | equity_swap_involved: false | shares_owned_after: 16,132.00 | transaction_form_type: 4 | Footnotes: F2, F5, F1
    • Sold 2 shares of Common Stock at $82.45 per share (Direct)
      Date: 2026-06-15 | Code: S | equity_swap_involved: false | shares_owned_after: 16,130.00 | transaction_form_type: 4 | Footnotes: F2, F1
    • Sold 40,000 shares of Stock option (right to buy) at $19.26 per share (Derivative)
      Date: 2026-06-15 | Code: M | Expires: 2032-02-02 | equity_swap_involved: false | shares_owned_after: 20,000.00 | transaction_form_type: 4 | Footnotes: F6

    Footnotes:

    • F1: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
    • F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
    • F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
    • F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
    • F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
    • F6: Fully exercisable.
    • REMARKS: The power of attorney under which this form was signed is on file with the Commission.

Search

News categories